Attached files

file filename
EX-99.1 - EXHIBIT 99.1 PRESS RELEASE - SEELOS THERAPEUTICS, INC.exhibit991pressreleasedate.htm


 
 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 17, 2014
Apricus Biosciences, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
Nevada
 
0-22245
 
87-0449967
 
 
 
 
 
(State or other jurisdiction of
incorporation)
 
(Commission File Number)
 
(I.R.S. Employer
Identification No.)
Registrant’s telephone number, including area code: (858) 222-8041
 
 
 
11975 El Camino Real, Suite 300, San Diego, California
 
92130
 
 
 
(Address of principal executive offices)
 
(Zip Code)
Not Applicable
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
 
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

1



Item 8.01     Other Events.

On March 17, 2014, Apricus Biosciences, Inc. issued a press release providing a corporate update and 2013 year-end financial results. A copy of the release is attached hereto as Exhibit 99.1.


Item 9.01.
Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit No.
 
Description
99.1
 
Press Release, dated March 17, 2014
 
 

2



SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
 
March 17, 2014
Apricus Biosciences, Inc.

 
 
By:
 /s/ Steve Martin
 
 
 
Steve Martin
 
 
 
Senior Vice President, Chief Financial Officer & Secretary
 


3